Review Frailty and [177Lu]Lu-PSMA-617 therapy: tools and strategies for older men with metastatic castration-resistant prostate cancer Full text PDF
Research Paper Dual-metallic porphyrinic MOFs with pH/ROS-responsive release for antibacterial and antioxidant therapy of diabetic infected wounds Full text PDF
Research Paper A multimodal pipeline for the identification and diagnostic immunoPET validation of hepatocellular carcinoma targets for radiotheranostic development Full text PDF
Research Paper An αvβ6/αvβ8-targeting peptibody inhibits integrin-dependent TGFβ activation, enables tumor-selective cytotoxic delivery, and synergizes with PD-L1 immune checkpoint blockade Full text PDF
Research Paper Radiocopper in BCMA-targeted immunotheranostics of myeloma Full text PDF
Research Paper Novel nastorazepide-based radioligands demonstrate effective cholecystokinin-2 receptor targeting with potential for theranostic applications Full text PDF
Issue 13; 2026
Founding Editor-in-Chief:
Prof. Xiaoyuan (Shawn) Chen, PhD
Profile
Theranostics publishes innovative research articles reflecting the fields of in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensors, system biology and translational medicine, personalized medicine and a broad spectrum of biomedical research that can be applied to future theranostic applications.
Background: Identifying tumor selective targets is critical for the development of precision diagnostic and therapeutic agents in oncology. Despite advances in precision oncology elsewhere, there are no FDA-approved hepatocellular carcinoma (HCC) antigen-selective antibody-drug conjugates or radiopharmaceuticals. This study establishes an integrated workflow to identify HCC-enriched plasma membrane targets and assess their suitability for targeted ...